ORAVERSE Drug Patent Profile

✉ Email this page to a colleague

When do Oraverse patents expire, and what generic alternatives are available?

Oraverse is a drug marketed by Septodont Holding and is included in one NDA.

The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oraverse

A generic version of ORAVERSE was approved as phentolamine mesylate by HIKMA on March 11^th, 1998.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ORAVERSE?
What are the global sales for ORAVERSE?
What is Average Wholesale Price for ORAVERSE?

Summary for ORAVERSE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	110
Clinical Trials:	6
Patent Applications:	1,014
Drug Prices:	Drug price information for ORAVERSE
What excipients (inactive ingredients) are in ORAVERSE?	ORAVERSE excipients list
DailyMed Link:	ORAVERSE at DailyMed

Drug patent expirations by year for ORAVERSE

Recent Clinical Trials for ORAVERSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cairo University	Phase 3
sara nabil	Phase 3
Dalhousie University	Phase 4

See all ORAVERSE clinical trials

Pharmacology for ORAVERSE

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

US Patents and Regulatory Information for ORAVERSE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ORAVERSE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	⤷ Sign Up	⤷ Sign Up
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	⤷ Sign Up	⤷ Sign Up
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for ORAVERSE

See the table below for patents covering ORAVERSE around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Denmark	1280531		⤷ Sign Up
Mexico	PA04012507	FORMULACIONES ESTABILIZADAS PARA ANTOAGONISTAS DEL RECEPTOR ALFA-ADRENERGICO Y USOS DE LAS MISMAS. (STABILIZED FORMULATIONS OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USES THEREOF.)	⤷ Sign Up
Israel	165599	תכשירים נוזליים יציבים המכילים אנטגוניסט לקולטן אלפא אדרנרגי במינון נמוך ושימושים בהם (Stable liquid compositions comprising a low dose alpha adrenergic receptor antagonist and uses thereof)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for ORAVERSE

Recent Clinical Trials for ORAVERSE

Pharmacology for ORAVERSE

Make Better Decisions: Try a trial or see plans & pricing